PRIDAM 4 MG / 4 ML SOLUCION INYECTABLE  I.V. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

pridam 4 mg / 4 ml solucion inyectable i.v.

laboratorios pisa, s.a. de c.v. - norepinefrina (bitartrato monohidratada) - norepinefrina (bitartrato monohidratada)....4,00 mg

Rasagiline Mylan European Union - English - EMA (European Medicines Agency)

rasagiline mylan

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva European Union - English - EMA (European Medicines Agency)

efavirenz/emtricitabine/tenofovir disoproxil zentiva

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir